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Despite the recent advances leading to the widespread use of
thrombolysis, aspirin, beta-blockade and angiotersin-
convening enzyme inhibitors, sudden death remains a major
probit.-m in the months after acute myocardial infarction . The
association of autonomic dysfunction with sudden death
after myocardial infarction has now been demonstrated by a
large number of clinical and experimental studies (1). Fur-
thermore, the detection of abnormalities of sympathovagal
tone reflected by reduced heart rate variability and barore-
ceptor sensitivity also provides a means of identifying pa-
tients at high risk of sudden death and ventricular arrhyth-
mias (2-5) .
Rationale for vagall stimulation after myocardial infarction .
To date, therapeutic maneuvers to improve sympathovagal
balance have mainly concentrated on reducing sympathetic
activity by beta-adrenergic blockade and in a small series,
left cervical sympathectomy (6,7). Both of these approaches
are associated with improved survival and a decreased risk
of sudden death after myocardial infarction . However, sym-
pathectomy is too invasive for routine clinical practice and
beta-blockade is associated with significant negative iso-
tropy and may not be tolerated by patients with airways
obstruction or peripheral vascular disease . An alternative
and potentially complementary strategy is to increase vagal
activity, and there is convincing experimental evidence to
suggest that this may be of value . Vanoli et al . (8), using the
exercise ischemia model in dogs with prior infarction (9),
showed that direct vagal stimulation was protective against
ventricular fibrillation although some of this protection was
lost when heart rate was maintained by atrial pacing . The
importance of the antifibrillatory influence of intrinsic vagal
activity was also shown by De Ferrari et al . (10), who
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reported that pre-administration of atropine led to worsening
of ventricular arrhythmias in 51% of 45 dogs that were
initially resistant to the combination of exercise and isch-
emia, although much of this deterioration may be rate
related . Similarly, the muscarinic agonist oxotremorine pre-
vented malignant ventricular arrhythmias in 13 of 15 cats
with reproducible arrhythmic responses to myocardial isch-
emia combined with left stellate ganglion stimulation (11) .
Conventional class I antiarrhythmic drugs were ineffective
in preventing ventricular arrhythmias in this model, whereas
the efficacy of amiodarone and beta-blockade was similar to
that of oxotremorine (12,13). There are also reports of the
value of other muscarinic agonists including carbachol (14)
and methacholine (15) in the prevention of ventricular ar-
rhythtnias ; similarly, the cholinesterase inhibitors edropho-
nium and neostigmine may he effective (1,16). Direct record-
ing from single vagal fibers in the cat showed that those
animals that were resistant to coronary occlusion had in-
creased vagal firing in response to both elevation in blood
pressure by phenylephrine and acute ischemia compared
with responses in animals that develop ventricular fibrilla-
tion (17) .
The present studies. The two studies by De Ferrari et al .
(18) and Vybiral et al . (19) reported in this issue of the
Journal examined the effect of low dose scopolamine acting
as a vagotonic agent on measures of autonomic function
after acute myocardial infarction . Both studies demonstrated
that conventional temporal measures of heart rate variability
were immediately improved by transdermal scopolamine . In
addition, the study by De Ferrari et al . showed favorable
changes in baroreceptor sensitivity and in the ratio of low
frequency/high frequency components of the heart rate
variability power spectrum . Some of the improvement in
these measures of autonomic function may be attributed to
the reduction in mean heart rate observed in both studies .
However, in the study by Vybiral et al, the changes in three
of the four time domain measures remained significant when
corrected for mean heart rate . The results of the two studies
are very similar and are in agreement with those of one other
recent report (20). It is also encouraging that the apparent
improvement in autonomic function is independent of other
cardiac drugs, allowing scope for a possible additive effect
with beta-blockade and angiotensin-converting enzyme inhi-
bition .
The mechanism of the vagotonic action of low dose
scopolamine is not well understood but is believed to be
mediated centrally (21) .
In the present studies there was a
fall in mean heart rate and an increase in heart rate variabil-
ity suggesting both an increase in basal vagal tone and
increased modulation around that basal level . Alternatively,
the changes may be due to increased sinus node responsive-
ness to vagal stimulation, but this would necessitate a
peripheral vagotonic action of scopolamine . Whatever the
mode of action of low dose scopolamine, the experimental
evidence suggests that it might be expected to reduce the
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propensity to ventricular arrhythmias by its effect on both
heart rate and heart rate variability .
Clinical =implications . These are the first clinical studies of
the effect of pharmacologic augmentation of vagal activity in
postinfarction patients
. The results suggest that short-term
manipulation of the autonomic nervous system is safe and
feasible but we are still a long way from showing a real
clinical benefit . Although depressed vagal activity is clearly
associated with increased risk of sudden death after infarc-
tion and the experimental evidence suggests a causal rela-
tionship, a large scale randomized trial would be required to
demonstrate a favorable effect of vagomimetic therapy on
survival. Before such a major undertaking could be justified,
additional information is required .
1) The present studies looked only at a single 24-hour
period of scopolamine administration and it is possible that
the beneficial effects may not be sustained . The majority of
sudden deaths occur during the Ist 3 months after infarction
which corresponds to the time course of spontaneous recov-
ery of heart rate variability and baroreceptor sensitivity
(22,23) . Accordingly, it is important to document that the
v tonic effects of scopolamine can be maintained over this
vulnerable period .
2) Both studies recruited patients with uncomplicated
infarction, many of whom were not at high risk . Although it
is encouraging that the patients with depressed heart rate
variability and baroreceptor sensitivity appeared to respond
particularly well to scopolamine, their numbers were ex-
tremely small. Confirmation of the efficacy of vagomimetic
therapy in the high risk subgroup of patients with impaired
autonomic function is required .
3) Potential adverse consequences of scopolamine ad-
ministration need to be considered . Although the incidence
of side effects reported in both studies was `ery low, with no
patches being removed prematurely, it remains to be seen if
long-term treatment is as well tolerated . There are also
theoretic risks from vagal stimulation . The development of
atrioventricular block (although not observed in the present
studies except during baroreceptor testing in a single patient)
is of some concern with the increasing awareness of the
importance of bradyarrhythmias as a cause of sudden car-
diac death (24) . Another potential problem is worsening of
myocardial ischemia as a consequence of cholinergically
mediated vasoconstriction in atherosclerotic vessels with
abnormal endothelium (25) . These issues need to be ad-
dressed in medium-term studies before proceeding to a full
scale randomized trial .
Although unlikely, it remains conceivable that autonomic
dysfunction is merely an epiphenomenon and treating it will
have no effect on survival
. Although markers of impaired
v activity are predictive of sudden death after infarction,
spectral measures of heart rate variability in the very low
frequency and ultra low frequency bands, which are not
clearly related to vagal activity, provide more powerful
independent predictors of risk than does the vagal high
frequency component (2
). Also, we should not forget a
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previous ill-fated study (2 ) in which apparently effective
reversal of a marker of increased risk resulted in an excess
mortality .
There are other groups of patients in whom augmentation
of vagal activity may prove to be of therapeutic value .
Sudden death and ventricular arrhythmias are a major prob-
lem in patients with heart failure, who also frequently show
similar autonomic dysfunction with depressed heart rate
variability (2 ). Scopolamine has similar apparently benefi-
cial effects in patients with heart failure (2
), a factor that
may be of particular clinical importance because it may
provide a means of modifying these patients' adverse sym-
pathovagal balance without the negative inotropic cost seen
with beta-blockade .
Conclusions . These are clearly only preliminary reports,
but the consistent results of these three similar studies have
shown that short-term manipulation of the autonomic ner-
vous system by pharmacologic vagal stimulation is feasible
and safe and may represent a novel therapeutic approach for
preventing life-threatening arrhythmias in postinfarction sur-
vivors and in other clinical settings. Further longer-term
studies need to be undertaken to demonstrate that the
apparently beneficial effect of scopolamine on the autonomic
nervous system can be maintained over a period of months .
Only if this proves to be the case will it be justified to
perform a major survival study to test the vw
;; that improv-
ing heart rate variability and baroreceptor sensitivity by
vagal stimulation will decrease mortality and risk of sudden
death after myocardial infarction .
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